IMCA medical center’s ethics committee approves clinical trial using proprietary CMND-100 treatment in Israel Tel Aviv, Israel / Vancouver, Canada, May 12, 2023 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the “company”), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health…


Previous articleGH Research Reports First Quarter 2023 Financial Results and Provides Business Highlights
Next articlePsychedelics Weekly – Multi-Stakeholder Capitalism, Psilocybin Service Centers Begin Opening in Oregon, and Vancouver’s ‘The Drugs Store’